mebeverine hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
mebeverine hydrochloride: clinical details
Prescribing considerations
- Investigate alarm symptoms, a new presentation or worsening symptoms rather than masking them with antispasmodic treatment.
- Paediatric licensing is formulation-specific: the selected suspension includes people aged 10 years and over, whereas the selected tablets and modified-release capsules are not recommended below 18 years.
- Check formulation excipients: tablets contain lactose, modified-release capsules contain sucrose, and suspension contains sodium, sodium benzoate and polyoxyl hydrogenated castor oil.
- Pregnancy and breastfeeding recommendations differ between formulations and specialist guidance; document an individual benefit–risk assessment.
Contraindications and cautions
- Hypersensitivity to mebeverine or any formulation excipient
- Relevant rare hereditary sugar-intolerance or malabsorption disorders where selected tablet or capsule excipients make use unsuitable
Monitoring
- No medicine-specific routine laboratory monitoring is specified in the selected product information.
- Review symptom response and reassess promptly if symptoms worsen, change or are accompanied by diagnostic red flags.
- When used during breastfeeding following specialist assessment, monitor the infant for allergic reactions or unusual behaviour.
Clinical pharmacology
Mebeverine is a direct-acting musculotropic antispasmodic. It is rapidly absorbed, extensively hydrolysed by esterases and eliminated mainly in urine as metabolites; significant accumulation is not expected.
Formulation and product differences
- Standard tablets should be swallowed whole and selected products contain lactose.
- Modified-release capsules must not be chewed and contain sucrose.
- The sugar-free oral suspension should be shaken well, contains sodium and preservative/excipient considerations, and has broader licensed wording that includes gastrointestinal spasm secondary to organic disease.
mebeverine hydrochloride preparations and strengths
Modified-release capsule
Route: Oral
Strengths: 200 mg
Oral suspension
Route: Oral
Strengths: 50 mg/5 mL
Tablet
Route: Oral
Strengths: 135 mg
mebeverine hydrochloride interactions
Formal interaction evidence is limited, and no clinically established medicine interactions are identified in the selected product information. Tell a healthcare professional about all prescribed, purchased and complementary products.
Alcohol
No interaction was demonstrated in animal studies, and patient information does not require alcohol avoidance specifically because of mebeverine.
Herbal remedies, vitamins and supplements
Interaction data are limited, so concurrent products should be checked when clinically relevant.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.